GHRP-2 may stimulate appetite and food intake in healthy men according to research data

Source: Laferrère B. et al., The Journal of Clinical Endocrinology & Metabolism , 2005, PMC2824650


Purpose of the study

To assess whether the peptide GHRP-2 (Growth Hormone Releasing Peptide-2) – a synthetic analogue of the hormone ghrelin – can increase appetite and food consumption in healthy people.

Ghrelin is the first peripheral hormone to directly stimulate hunger. It is produced primarily in the stomach and acts through GHS-R1a receptors to increase growth hormone (GH) levels and stimulate feeding.

The aim of this study was to test whether GHRP-2, which shares the same receptor, could mimic the effects of ghrelin in humans.



Study design

  • Type: double-blind, placebo-controlled, crossover

  • Participants: 7 healthy men (mean age 26 years, BMI 22.8 kg/m²)

  • Interventions:


    • GHRP-2 infusion (1 µg/kg/hour) for 270 minutes

    • Control session: placebo (0.9% NaCl) of the same duration


  • Nutritional test: after the end of the infusion, participants are given access to a free-choice buffet to measure spontaneous energy intake

  • Measurements:


    • Energy intake (total calorie intake, macronutrients)

    • GH, glucose, insulin levels

    • Subjective feeling of hunger (visual scales)


Main results

Food intake


  • GHRP-2 leads to a significant increase in energy intake:


    • +35.9% vs. placebo

    • GHRP-2: 136.0 ± 13.0 kJ/kg

    • Placebo: 101.3 ± 10.5 kJ/kg ( p = 0.008 )


  • The composition of the food (proteins, carbohydrates, fats) does not differ significantly.

  • Participants began eating earlier after the GHRP-2 infusion.



Hormonal response

  • GH rises sharply during infusion:

    • GHRP-2: 5550 ± 1090 µg/L/240 min

    • Placebo: 412 ± 161 µg/L/240 min ( p = 0.003 )


  • Insulin and glucose remain stable.

  • No side effects were observed.



Subjective sensations

  • The feeling of hunger and desire to eat increases synchronously with the increase in GH.

  • The effect is temporary and disappears 1–2 hours after stopping the infusion.



Conclusions

  • GHRP-2 stimulates food intake in healthy people.

  • This is the first evidence that a peptide activating the GHS-R1a receptor can induce real hunger and increased calorie intake.

  • It acts centrally (in the hypothalamus) and peripherally, activating neural pathways related to appetite.

  • It has potential use in conditions with reduced appetite (anorexia, cachexia, sarcopenia).

  • The effect on GH indicates a possible dual benefit – stimulation of appetite and anabolism.



Restrictions

  • Small number of participants (n=7)

  • Only men of normal weight

  • Single infusion – does not show long-term effect

  • Not studied in overweight people



Practical importance

  • GHRP-2 can be used in clinical conditions with decreased appetite.

  • It increases GH and can aid recovery and muscle growth.

  • Its action is short-lived and controllable, suitable for research purposes.